Physician profile
Robert R Hightower
NPI 1548296312
$1,155.31
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $124 · 2021: $203 · 2022: $131 · 2023: $192 · 2024: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $319.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $347.53 | 2019-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Pfizer INC. | $160.22 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.98 | 2020-2022 | |
| Corium, LLC | $83.51 | 2023-2024 | Azstarys |
| Sanofi Pasteur INC. | $77.72 | 2021-2023 | |
| Cranial Technologies, INC | $75.92 | 2019-2024 | Doc Band |
| Sobi, INC | $71.73 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $42.56 | 2019 | |
| Seqirus USA INC | $31.16 | 2021-2022 | |
| Tris Pharma INC | $26.40 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.42 | 2023 | Flumist Quadrivalent |
| Quidel Corporation | $20.98 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.24 | 2022 | |
| Adlon Therapeutics L.P. | $14.35 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.30 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hightower listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.